Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EBITDA (2019 - 2026)

Pliant Therapeutics has reported EBITDA over the past 8 years, most recently at -$20.4 million for Q1 2026.

  • Quarterly EBITDA rose 63.84% to -$20.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$113.7 million through Mar 2026, up 48.04% year-over-year, with the annual reading at -$149.7 million for FY2025, 28.83% up from the prior year.
  • EBITDA was -$20.4 million for Q1 2026 at Pliant Therapeutics, up from -$23.6 million in the prior quarter.
  • Over five years, EBITDA peaked at -$20.4 million in Q1 2026 and troughed at -$56.3 million in Q1 2025.
  • The 5-year median for EBITDA is -$38.9 million (2023), against an average of -$39.1 million.
  • Year-over-year, EBITDA plummeted 41.02% in 2023 and then skyrocketed 63.84% in 2026.
  • A 5-year view of EBITDA shows it stood at -$34.6 million in 2022, then decreased by 12.42% to -$38.9 million in 2023, then dropped by 29.34% to -$50.3 million in 2024, then surged by 52.99% to -$23.6 million in 2025, then rose by 13.8% to -$20.4 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's EBITDA are -$20.4 million (Q1 2026), -$23.6 million (Q4 2025), and -$26.3 million (Q3 2025).